Monte Rosa Therapeutics, Inc.

The momentum for this stock is not very good. Monte Rosa Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Monte Rosa Therapeutics, Inc..

News

Monte Rosa Therapeutics announces first participants dosed in MRT-6160 study

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Globe Newswire MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases...\n more…

Monte Rosa Therapeutics price target lowered by $1 at Wells Fargo, here's why

Monte Rosa Therapeutics GAAP EPS of -$0.43, revenue of $4.7M

SeekingAlpha.com: All News Monte Rosa Therapeutics reports Q2 2024 financial results with Collaboration Revenue of $4.7M.\n more…

GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nGLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second...\n more…

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.71 per share a year ago. These...\n more…